Open-Label Clinical Trial Evaluating the Impact of a Multi-Strain Commensal Probiotic Dietary Supplement on Gastrointestinal Microbiota Composition, Functional Gastrointestinal Markers, and Gastrointestinal Symptoms

NCT07720362 — Not applicable, Not yet recruiting, 25 participants, OvationLab

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT07720362
StatusNot yet recruiting
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, other
Enrollment25 (Estimated)
SponsorOvationLab (Network)
ConditionsGastrointestinal, Microbiota
InterventionsComplete Commensal Probiotic (Dietary supplement)
Datesstart 2026-07-21 (estimated), primary completion 2026-11-01 (estimated), completion 2026-11-01 (estimated), first posted 2026-07-22, last updated 2026-07-23
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Gastrointestinal All trials for Microbiota All trials of Complete Commensal Probiotic

-Summary

A single-arm, open-label prospective study will be conducted evaluating the impact of 8 weeks of supplementation at the manufacturer-recommended dose of Complete Commensal Probiotic™ on the GI-MAP stool test panel (Diagnostic Solutions Laboratory, Alpharetta, GA), gastrointestinal symptoms, digestion-associated quality of life. and overall physical health, mental health, and anxiety.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Complete Commensal ProbioticExperimentalDietary Supplement: Complete Commensal Probiotic
  • Complete Commensal Probiotic (Dietary supplement): Complete Commensal Probiotic™ contains five established commensal strains selected for their documented physiologic roles in the healthy adult gut. The five commensal strains in the product in this study are Akkermansia muciniphila (TA09), Bifidobacterium adolescentis (TA38), Bifidobacterium longum (TA24), Faecalibacterium prausnitzii (TA35), and Roseburia intestinalis (TA08).

+Outcome measures

Primary outcomes

  • Relative Abundance of Commensal Microorganisms [Baseline and end of 8-week intervention]: Counts of microbes per gram of each organism on GI-MAP test

Secondary outcomes

  • Functional and Microbial Markers of Intestinal Health [Baseline and end of 8-week intervention]: Functional and microbial markers of intestinal health on the GI-MAP will be categorized as low, medium, and high
  • Gastrointestinal Symptoms Rating Scale [Baseline and end of 8-week intervention]: Validated questionnaire assessing gastrointestinal symptoms. Total scores across all domains range from 15-105. Higher scores indicate worse gastrointestinal symptoms.
  • Digestion-Associated Quality of Life Questionnaire [Assessed at baseline and end of 8-week study.]: Validated questionnaire assessing the impact of digestion on quality of life. Total scores across all domains range from 0 to 81. Higher scores indicate worse digestion-associated quality of life.
  • PROMIS - Global Health [Baseline and end of 8-week study.]: Validated questionnaire assessing global physical and mental health. T scores range from 16.2 to 67.7 for physical health and from 21.2 to 67.6 for mental health. Higher scores indicate better physical and mental health.
  • PROMIS - Anxiety Short Form 8a [Assessed at baseline and end of 8-week study.]: Validated questionnaire assessing feelings of anxiety. T scores range from 37.1 to 83.1. Higher scores indicate greater feelings of anxiety.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. Adult females or males age ≥ 18 years
2. At least moderate gastrointestinal distress, defined as a score of ≥ 4 on any domain of the Gastrointestinal Symptoms Rating Scale (GSRS) at screening
3. Ability to read and speak English
4. Ability and willingness to collect an at-home stool sample for GI-MAP testing

Exclusion Criteria:

1. Current or recent (within the prior 90 days) use of a probiotic dietary supplement
2. Current or recent (within the prior 90 days) use of systemic antibiotics, antifungals, or antiparasitic medications
3. Known allergies to any ingredients in the product
4. Currently pregnant or lactating women or women planning to become pregnant in the next 8 weeks
5. Current diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis), celiac disease, active gastrointestinal malignancy, or other chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
6. Severely immunocompromised status (e.g., active chemotherapy, post-transplant immunosuppression, advanced HIV)
7. Participants unable to provide consent

+Locations (1)

FacilityCityCountryStatus
OvationLabRichmond, VirginiaUnited States